Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decipher a 300-page biopharma filing packed with clinical endpoints and FDA jargon can stall even seasoned analysts. Madrigal Pharmaceuticals’ SEC documents are no exception: every 10-K details Rezdiffra’s trial design, while 8-Ks flag pivotal data releases that can move the stock overnight. If you have searched for “Madrigal Pharmaceuticals SEC filings explained simply,” you know the challenge.
Stock Titan cuts through that complexity. Our AI reads each Madrigal Pharmaceuticals quarterly earnings report 10-Q filing, highlights cash-runway updates, and links them to ongoing MAESTRO studies. Need fast context on a sudden press release? We deliver Madrigal Pharmaceuticals 8-K material events explained in plain English within minutes of EDGAR posting. Real-time alerts surface Madrigal Pharmaceuticals Form 4 insider transactions, so you can follow executive stock trades ahead of regulatory milestones. You will also find the annual report—Madrigal Pharmaceuticals annual report 10-K simplified—and an easy path to the Madrigal Pharmaceuticals proxy statement executive compensation that breaks down R&D-driven pay packages.
Whether you are monitoring Madrigal Pharmaceuticals insider trading Form 4 transactions, comparing Phase 3 expenses line-by-line, or seeking a concise Madrigal Pharmaceuticals earnings report filing analysis, our platform equips you to act decisively. AI-powered summaries, expert tagging, and comprehensive coverage of every form—10-K, 10-Q, 8-K, S-3, plus Madrigal Pharmaceuticals executive stock transactions Form 4 in real time—mean fewer hours lost and more insights gained. Start understanding Madrigal Pharmaceuticals SEC documents with AI instead of wrestling with them.
Madrigal Pharmaceuticals disclosed an insider transaction by a company director on December 10, 2025. The director acquired 24,800 shares of common stock at $15.8 per share and, on the same day, sold 24,800 shares in multiple open-market trades at weighted average prices described in several ranges between approximately $547 and $555, all under a Rule 10b5-1 trading plan adopted on September 10, 2025.
After these transactions, the director beneficially owned 187,164 shares directly and 655,540 shares indirectly through SQN LLC, where the director and spouse are managing members and disclaim beneficial ownership beyond any pecuniary interest.
Madrigal Pharmaceuticals director reported several stock transactions dated 12/10/2025. The reporting person exercised a stock option to acquire 18,650 shares of common stock at $15.8 per share, then sold multiple blocks of shares the same day under a Rule 10b5-1 trading plan adopted on September 10, 2025 at weighted-average prices reported between $547.16 and $555.31 per share, plus an additional sale at $555.39 per share.
The reporting person also made a charitable contribution of 5,455 shares of common stock to a donor advised fund. After these transactions, they held 455,589 shares directly and 655,540 shares indirectly through SQN LLC, where the reporting person and a spouse are managing members, with beneficial ownership of those indirect shares disclaimed except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals (MDGL) reported that its Chief Commercial Officer filed a Form 4 disclosing multiple sales of common stock on 11/21/2025. One sale of 894 shares was made by the company on the officer’s behalf to cover tax withholding tied to vesting of restricted stock units and was automatic, not at the officer’s discretion. Additional market sales were executed the same day in small blocks under a Rule 10b5-1 trading plan adopted on November 5, 2024, at weighted average prices generally between about $547 and $565 per share. Following these transactions, the officer directly beneficially owned 10,032 shares of Madrigal common stock.
Madrigal Pharmaceuticals (MDGL) reported insider activity by a director on 11/13/2025. The filing shows two option exercises and subsequent open‑market sales executed under a Rule 10b5‑1 trading plan adopted on August 14, 2025.
The director exercised stock options for 2,500 shares at an exercise price of $7.36 and 6,000 shares at $16.46. Following the exercises, multiple sales occurred the same day across several tranches at weighted average prices, with disclosed ranges from $514.03 to $528.94 per share. After these transactions, the filing lists 21,197 shares of common stock beneficially owned on a direct basis.
The option entries indicate the underlying shares were fully vested and exercisable. Price footnotes state each reported sale price is a weighted average, with full trade‑level details available upon request.
Madrigal Pharmaceuticals (MDGL) director reported option exercises and share sales. On 11/05/2025, the insider exercised stock options for 5,470 shares at $9.45, 10,000 shares at $303.79, and 1,105 shares at $280.04 (all fully vested). The insider then sold multiple blocks of common stock, with weighted-average sale prices ranging from about $480.2397 to $490.9817, as detailed in footnotes. After these transactions, the insider directly beneficially owned 2,627 shares.
Madrigal Pharmaceuticals (MDGL) reported a sharp commercial ramp for Rezdiffra as product revenue reached $287.3 million in Q3 2025, up from $62.2 million a year ago. For the nine months ended September 30, 2025, product revenue totaled $637.3 million versus $76.8 million in 2024.
The company posted a net loss of $114.2 million for Q3 and $229.7 million year-to-date, reflecting higher selling, general and administrative expenses tied to commercialization and increased R&D. Liquidity remained strong with cash, cash equivalents and marketable securities of $1.11 billion, while long‑term debt rose after funding a $350.0 million initial term loan under a new credit facility that provides up to $500.0 million in commitments and requires at least $100.0 million of unrestricted cash. Accrued liabilities include a $117.3 million CSPC license upfront expense accrued and paid in October.
Rezdiffra received European Commission approval in August 2025 and launched in Germany in September, adding an early ex‑U.S. foothold alongside U.S. sales.
Madrigal Pharmaceuticals (MDGL)
The information is furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Madrigal Pharmaceuticals (MDGL) submitted a Form 144 reporting proposed and recent insider sales of common stock. The filer disclosed a proposed sale of 7,279 shares through Morgan Stanley Smith Barney with an aggregate market value of $3,303,210.20, listing Nasdaq as the exchange and an approximate sale date of 09/09/2025. The shares were acquired as a Restricted Stock Unit grant that vested on 09/08/2025 and the payment/nature of the transaction is recorded as vesting of RSUs. The filing also reports that William John Sibold sold 7,616 shares on 08/21/2025 for $3,047,756.28. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.
William John Sibold, President, CEO and a director of Madrigal Pharmaceuticals, Inc. (MDGL), reported a sale of 7,279 shares of common stock on 09/09/2025 at a reported price of $445.63 per share. The filing states the shares were sold by the issuer on the reporting person’s behalf to cover tax withholding obligations related to the vesting of restricted stock units. After the transaction, Mr. Sibold beneficially owned 102,474 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Madrigal Pharmac (MDGL)?
What is the market cap of Madrigal Pharmac (MDGL)?
